Wells Fargo
DMAC icon

Wells Fargo’s DiaMedica Therapeutics DMAC Stock Holding History

Wells Fargo’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$108K Sell
15,966
-24,663
-61% -$195K ﹤0.01% 5071
2025
Q4 		$323K Buy
40,629
+18,682
+85% +$140K ﹤0.01% 4787
2025
Q3 		$151K Buy
21,947
+7,295
+50% +$39.6K ﹤0.01% 5086
2025
Q2 		$57.1K Buy
14,652
+13,652
+1,365% +$53.2K ﹤0.01% 5465
2025
Q1 		$3.79K Buy
+1,000
New +$5.72K ﹤0.01% 6071
2024
Q2 		– Sell
-175
Closed -$485 – 7035
2024
Q1 		$485 Buy
175
+3
+2% +$9 ﹤0.01% 6285
2023
Q4 		$488 Buy
172
+9
+6% +$22 ﹤0.01% 6388
2023
Q3 		$421 Buy
163
+47
+41% +$151 ﹤0.01% 6401
2023
Q2 		$501 Buy
116
+4
+4% +$10 ﹤0.01% 6489
2023
Q1 		$171 Buy
112
+2
+2% +$3 ﹤0.01% 6817
2022
Q4 		$174 Buy
110
+3
+3% +$4 ﹤0.01% 6655
2022
Q3 		$0 Sell
107
-70
-40% -$109 ﹤0.01% 6777
2022
Q2 		$0 Buy
177
+14
+9% +$33 ﹤0.01% 6922
2022
Q1 		$0 Buy
163
+1
+0.6% +$3 ﹤0.01% 7190
2021
Q4 		$1K Buy
162
+47
+41% +$185 ﹤0.01% 6987
2021
Q3 		$0 Buy
115
+10
+10% +$38 ﹤0.01% 7040
2021
Q2 		$0 Sell
105
-1
-0.9% -$8 ﹤0.01% 6977
2021
Q1 		$1K Sell
106
-2,000
-95% -$18.7K ﹤0.01% 6701
2020
Q4 		$21K Buy
2,106
+31
+1% +$170 ﹤0.01% 5844
2020
Q3 		$8K Buy
2,075
+8
+0.4% +$42 ﹤0.01% 5930
2020
Q2 		$14K Buy
2,067
+2,000
+2,985% +$8.92K ﹤0.01% 5775
2020
Q1 		$0 Buy
+67
New +$277 ﹤0.01% 6300

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wells Fargo's DMAC Position: Q1 2026 in Review

Wells Fargo reduced its DiaMedica Therapeutics (DMAC) stake by 61% in Q1 2026, selling an estimated $195K and leaving 15,966 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #5071.

Wells Fargo first reported a position in DMAC in Q1 2020 and has held it in 22 quarters since. The position peaked at $323K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Wells Fargo held 15,966 shares of DiaMedica Therapeutics worth $108K as of Q1 2026.
  • Wells Fargo sold 24,663 DiaMedica Therapeutics shares in Q1 2026, an estimated $195K.
  • DiaMedica Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5071 holding.
  • Wells Fargo first reported a position in DiaMedica Therapeutics in Q1 2020 and has held it in 22 quarters since.
  • Wells Fargo's DiaMedica Therapeutics position peaked at $323K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.